Importance of the Australian Crohn's Disease Antibiotic Study

Gastroenterology

Volumn 133, Issue 5, 2007, Pages 1744-1745

  Chamberlin, William ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; CLOFAZIMINE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; RIFABUTIN;

ANFTIBIOTIC THERAPY; COMBINATION CHEMOTHERAPY; CROHN DISEASE; HUMAN; LETTER; MYCOBACTERIUM AVIUM; MYCOBACTERIUM PARATUBERCULOSIS; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; CLOFAZIMINE; CROHN DISEASE; DATA INTERPRETATION, STATISTICAL; DRUG THERAPY, COMBINATION; HUMANS; MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS; PARATUBERCULOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIFABUTIN; TREATMENT OUTCOME;

EID: 35648978201     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.09.013     Document Type: Letter

References (6)

1. Selby W., Pavill P., Crotty B., et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 132 (2007) 2313-2319
2. Peyrin-Biroulet L., Neut C., and Columbel J.F. Antimycobacterial therapy in Crohn's disease; game over?. Gastroenterology 132 (2007) 2594-2598
3. Greenstein R.J., Liya S., Haroutunian V., et al. On the action of methotrexate and 6-mercaptopurine on M. avium subspecies paratuberculosis. PLos One 2 (2007) e161
4. Greenstein R.J., Su L., Shahidi A., et al. On the action of 5-amino-salicylic acid and sulfapyridine on M. avium subspecies paratuberculosis. PLos One 2 (2007) e516
5. Mannon P. Gain for loss: adalimubab for infliximab-refractory Crohn disease. Ann Intern Med 146 (2007) 888-890
6. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the Accent/Randomised trial. Lancet 359 (2002) 1541-1549